【摘要】 目的通过不同剂量瑞舒伐他汀治疗急性冠状动脉综合征(acute coronary syndrome,ACS)患者前、后血清Legumain浓度的变化,探讨强化他汀类药物治疗对Legumain蛋白与冠状动脉粥样硬化斑块的影响。方法用酶联免疫吸附试验(ELISA)法测定120例ACS患者使用不同剂量瑞舒伐他汀治疗前、后外周静脉血清Legumain浓度,其中常规治疗组40例,强化治疗A组40例,强化治疗B组40例。结果(1)三组患者血清Legumain浓度在不同剂量瑞舒伐他汀治疗4周过程中均呈逐步下降趋势(P<0.05);(2)治疗4周时,强化治疗B组血清Legumain浓度与常规治疗组比较,差异有统计学意义(P<0.05);(3)强化治疗B组与常规治疗组左心室功能和校正心肌梗死溶栓试验(thrombolysis in myocardial infarction,TIMI)计帧数(CTFC)比较,差异均有统计学意义(P<0.05);(4)治疗4周时,强化治疗B组与强化治疗A组、强化治疗A组与常规治疗组间Legumain浓度和其他临床结果比较,差异均无统计学意义(P>0.05);(5)第4周时,3组间的药物不良反应和主要不良心血管事件发生率比较,差异均无统计学意义(P>0.05)。结论 Legumain有望作为监测和评估ACS患者的指标;强化瑞舒伐他汀治疗可降低血清Legumain浓度,改善患者左心室功能和校正TIMI计帧数,同时,其不良反应无增加。更多还原

【Abstract】 Objectives To probe the impact of rosuvastatin therapy and its relationship with Legumain protein andcoronary atherosclerotic plaques by detecting the changes of serum concentration of Legumain-protein in patients withacute coronary syndrome(ACS)after treatment with different doses of rosuvastatin.Methods Forty ACS patients ofconventional therapy group,40 ACS patients of intensive treatment A group and 40 ACS patients of intensive treatmentB group was included.Blood of patients was aspirated from peripheral veins.Enzyme linked immunosorbent assay(ELISA)was used to assay serum concentrations of Legumain before and after treatment.Results(1)Serum concentrationsof Legumain of the three groups after 4 weeks of different doses rosuvastatin treatment showed a gradual downward trend(P<0.05);(2)After 4 weeks′ treatment,there was a significant difference in serum concentration of Legumainbetween intensive treatment B group and conventional therapy group(P<0.05);(3)There were statistical significancesof left ventricular function and calibration thrombolysis myocardial infarction(TIMI)frame count(CTFC)betweenintensive treatment B group and conventional therapy group(P<0.05);(4)Serum concentrations of Legumain andclinical outcomes had no statistical differences comparing intensive treatment B group and intensive treatment A groupas well as intensive treatment A group and conventional therapy group at the fourth week(P>0.05);(5)Adversedrug reactions and major adverse cardiovascular events among the three groups had no statistical differences atthe fourth week(P>0.05).Conclusions Serum concentration of Legumain may be used as an monitoring and assessingindicator for ACS patients;intensive rosuvastatin therapy can decrease serum concentration of Legumain,improveleft ventricular function and TIMI CTFC without increasing adverse reactions.更多还原